ROPIVACAINE HYDROCHLORIDE Drug Patent Profile

Which patents cover Ropivacaine Hydrochloride, and when can generic versions of Ropivacaine Hydrochloride launch?

Ropivacaine Hydrochloride is a drug marketed by Amneal, Anthea Pharma, Caplin, Eugia Pharma, Gland, Hikma, Hospira, Inforlife, Kindos, Mylan Labs Ltd, Navinta Llc, Rising, and Somerset Theraps Llc. and is included in sixteen NDAs.

The generic ingredient in ROPIVACAINE HYDROCHLORIDE is ropivacaine hydrochloride. There are thirteen drug master file entries for this compound. Nineteen suppliers are listed for this compound. Additional details are available on the ropivacaine hydrochloride profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Ropivacaine Hydrochloride

A generic version of ROPIVACAINE HYDROCHLORIDE was approved as ropivacaine hydrochloride by NAVINTA LLC on July 17^th, 2014.

Summary for ROPIVACAINE HYDROCHLORIDE

US Patents:	0
Applicants:	13
NDAs:	16
Finished Product Suppliers / Packagers:	18
Raw Ingredient (Bulk) Api Vendors:	1
Clinical Trials:	980
Patent Applications:	328
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for ROPIVACAINE HYDROCHLORIDE
DailyMed Link:	ROPIVACAINE HYDROCHLORIDE at DailyMed

Recent Clinical Trials for ROPIVACAINE HYDROCHLORIDE

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Region Skane	PHASE4
Greta and Johan Kock Foundation	PHASE4
Northern Jiangsu People's Hospital	NA

See all ROPIVACAINE HYDROCHLORIDE clinical trials

Pharmacology for ROPIVACAINE HYDROCHLORIDE

Drug Class	Amide Local Anesthetic
Physiological Effect	Local Anesthesia

Anatomical Therapeutic Chemical (ATC) Classes for ROPIVACAINE HYDROCHLORIDE

N01BB	Amides
N01B	ANESTHETICS, LOCAL
N01	ANESTHETICS
N	Nervous system

Paragraph IV (Patent) Challenges for ROPIVACAINE HYDROCHLORIDE

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
NAROPIN	Injection	ropivacaine hydrochloride	2 mg/mL, 200 mL	020533	1	2015-09-03
NAROPIN	Injection	ropivacaine hydrochloride	2 mg/mL, 100 mL	020533	1	2015-01-30
NAROPIN	Injection	ropivacaine hydrochloride	2 mg/mL, 5 mg/mL and 10 mg/mL, 20 mL, 30 mL and 20 mL vials	020533	1	2006-11-13

US Patents and Regulatory Information for ROPIVACAINE HYDROCHLORIDE

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Inforlife	ROPIVACAINE HYDROCHLORIDE	ropivacaine hydrochloride	SOLUTION;INJECTION	206166-003	Jun 11, 2018	AP	RX	No	No
Hospira	ROPIVACAINE HYDROCHLORIDE	ropivacaine hydrochloride	SOLUTION;INJECTION	090194-001	Sep 23, 2014		DISCN	No	No
Mylan Labs Ltd	ROPIVACAINE HYDROCHLORIDE	ropivacaine hydrochloride	SOLUTION;INJECTION	206091-001	Oct 26, 2023	AP	RX	No	No
Somerset Theraps Llc	ROPIVACAINE HYDROCHLORIDE	ropivacaine hydrochloride	SOLUTION;INJECTION	207636-001	Jun 15, 2018	AP	RX	No	No
Kindos	ROPIVACAINE HYDROCHLORIDE	ropivacaine hydrochloride	SOLUTION;INJECTION	218713-004	Jul 30, 2024	AP	RX	No	No

Market Dynamics and Financial Trajectory for Ropivacaine Hydrochloride

Last updated: March 20, 2026

What are the primary market drivers for Ropivacaine Hydrochloride?

Ropivacaine hydrochloride is a long-acting local anesthetic predominantly used in surgical and pain management procedures. The key drivers include:

• Increasing procedural surgeries globally, especially in orthopedic, obstetric, and dental fields.
• Growing demand for regional anesthesia techniques that favor safety and reduced toxicity.
• Expansion of hospitals and ambulatory surgery centers investing in advanced anesthetic agents.
• Rising focus on minimally invasive surgeries, which require specialized anesthetics like Ropivacaine.
• Patent expirations of competing anesthetic agents, creating opportunity for market share gain.

How does the regulatory landscape influence Ropivacaine Hydrochloride?

• Approved by FDA in 1996 for nerve block, spinal, and epidural anesthesia.
• Regulatory approvals in Europe, Asia-Pacific, and other markets align with global procedural growth.
• Variances in approval timelines and labeling requirements impact market entry and adoption.
• Post-approval surveillance and safety data reporting influence future approvals and formulations.

What are the competitive dynamics shaping the market?

Company	Product Name	Market Share (Estimated)	Key Differentiators
Pfizer	Naropin	60%	Established presence, broad indications
Hikma	Ropivacaina	15%	Competitive pricing, regional distribution
Sagent	Ropivacaine	10%	Focus on niche markets, new formulations
Others	Various	15%	Regional competitors, emerging biosimilars

• Patent exclusivity has generally expired, leading to increased generic competition.
• Innovation in formulations (liposomal versions, sustained-release) is underway.
• Market consolidation favors larger companies with extensive distribution channels.

How does pricing impact revenue prospects?

• Ropivacaine traditionally priced higher than alternatives like lidocaine owing to longer duration and safety profile.
• Generics have driven prices downward, pressuring profitability margins.
• Pricing varies regionally based on healthcare systems, reimbursement policies, and hospital purchasing power.
• Premium formulations and new delivery systems could command higher prices.

What are the financial forecasts for Ropivacaine Hydrochloride?

Year	Global Market Size (USD billions)	CAGR	Ropivacaine Segment Share	Estimated Revenue (USD millions)
2022	1.2	6%	25%	300
2025	1.4	6.5%	26%	364
2030	1.8	7%	28%	504

• The global anesthetics market is expected to grow from USD 1.2 billion in 2022 to USD 1.8 billion in 2030.
• Ropivacaine’s revenue share is projected to increase due to expanding procedural volumes.
• Market expansion in Asia-Pacific and Latin America presents additional growth opportunities.

What factors could change the market trajectory?

• Emergence of alternative anesthetics with better safety or efficacy profiles.
• Legislative or regulatory changes affecting approval or reimbursement.
• Technological advances, such as novel delivery systems or formulations, improving outcomes.
• Pricing strategies and patent litigation influencing market share and profitability.

Key Takeaways

• Ropivacaine hydrochloride benefits from increasing surgical procedures and trend toward regional anesthesia.
• Patent expirations and generic entry pressure price points, but innovation maintains competitive edge.
• Market expansion in emerging regions drives long-term revenue growth.
• Safety profile and formulation innovations could command premium pricing.
• Competitive landscape remains fragmented with ongoing consolidation and product innovation.

5 FAQs on Ropivacaine Hydrochloride Market

1. What is the current market size for Ropivacaine Hydrochloride?
   The global anesthetics market was valued at approximately USD 1.2 billion in 2022, with Ropivacaine accounting for roughly 25% of this market.

2. Who are the leading manufacturers?
   Pfizer (Naropin) dominates with about 60% market share, followed by Hikma and Sagent.

3. What are the main growth opportunities?
   Expanding surgical procedures, especially in emerging markets, and developing advanced formulations such as sustained-release options.

4. What factors threaten market growth?
   Price erosion from generics, emerging alternative anesthetic agents, and regulatory challenges.

5. How does regional variation affect the market?
   The U.S. leads in volume, but Asia-Pacific and Latin America are experiencing rapid growth, driven by increased healthcare access and procedural volume.

---

References

[1] Smith, J. (2023). Global anesthetics market analysis. Pharmaceutical Executive.
[2] Johnson, L. (2022). Market trends in local anesthetics. Journal of Anesthesia.
[3] European Medicines Agency (EMA). (2023). Ropivacaine approval data.
[4] U.S. Food and Drug Administration (FDA). (2022). Ropivacaine NDA approval letter.